Trinity Biotech (TRIB) Projected to Announce Earnings on Thursday

Trinity Biotech (NASDAQ:TRIB) is expected to be releasing its Q2 2026 resultson Thursday, September 3rd. Analysts expect the company to announce earnings of ($7.80) per share and revenue of $10.3110 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, September 11, 2026 at 4:00 PM ET.

Trinity Biotech (NASDAQ:TRIB) last announced its quarterly earnings results on Tuesday, June 16th. The company reported ($6.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($9.30) by $2.40. The company had revenue of $10.85 million for the quarter, compared to the consensus estimate of $10.68 million.

Trinity Biotech Price Performance

TRIB stock opened at $9.72 on Wednesday. The stock has a market cap of $7.87 million, a price-to-earnings ratio of -0.22 and a beta of 0.75. The company has a 50 day simple moving average of $11.05 and a 200 day simple moving average of $16.92. Trinity Biotech has a 1 year low of $7.94 and a 1 year high of $52.50.

Institutional Investors Weigh In On Trinity Biotech

A hedge fund recently bought a new stake in Trinity Biotech stock. Perceptive Advisors LLC purchased a new stake in Trinity Biotech PLC (NASDAQ:TRIB) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,790,000 shares of the company’s stock, valued at approximately $1,164,000. Perceptive Advisors LLC owned 9.92% of Trinity Biotech at the end of the most recent quarter. 78.97% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Trinity Biotech from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 20th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

About Trinity Biotech

Trinity Biotech plc is a global diagnostic healthcare company headquartered in Bray, Ireland. The firm specializes in the development, manufacture and marketing of in vitro diagnostic products aimed at the detection and management of chronic and infectious diseases. Its offerings are designed to deliver timely and accurate results for a range of healthcare settings, from central laboratories to point?of?care environments.

The company’s product portfolio includes a comprehensive array of assays and instrumentation.